Clinical Trial

Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)

Name: Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) — clinical trial record (NCT07712588)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This study will treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of birelentinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP.

Trial Details

NCT Number	NCT07712588
Lead Sponsor	Dizal Pharmaceuticals
Conditions	Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment	880 participants
Start Date	2026-09
Primary Completion	2031-01 (estimated)
Study Completion	2032-02 (estimated)
Updated on ClinicalTrials.gov	2026-08-05